About
The Clinical BioManufacturing Facility is the University of Oxford’s GMP (Good Manufacturing Practice) manufacturing facility.
The Clinical BioManufacturing Facility has over 20 years experience producing biological Investigational Medicinal Products (IMPs) according to the principles of GMP for early phase clinical trials. We hold a Manufacturer’s Authorisation for Investigational Medicinal Products (MIA (IMPs)) from the Medicines and Healthcare products Regulatory Agency (MHRA), which allows us to manufacture a variety of products including viral vector and recombinant protein vaccines and advanced therapy medicinal products (ATMPs) such as cell and gene therapy products. All IMPs are manufactured and released in accordance with the European Clinical Trials Directive (2004). The facility can also import IMPs from outside the EU for use in clinical trials within the European Union.
We aim to provide the link between academic research and clinical drug development, to allow all our collaborators to make rapid progress into clinical trials.
Our GMP manufacturing facility enables us to meet the special demands for phase I/II clinical trials of novel biotech products within the academic and commercial sectors and to deliver effective short term treatments to the clinic providing long term benefits to the patient.
News
Moh Family Foundation visit highlights vital support for pandemic preparedness research
24 October 2024
The Pandemic Sciences Institute welcomed the Moh Family Foundation to Oxford to share latest research updates and celebrate the Foundation’s generous support.
Large-scale study on Long Covid highlights urgent, global need for investment
22 October 2024
A new study in BMJ Global Health reveals the key Long Covid characteristics affecting populations worldwide, including fatigue, shortness of breath and having trouble thinking clearly. 6-12 months after hospital discharge, 70% of study participants were affected by Long Covid in high-income countries, and 42% in low and middle-income countries.
Study suggests possible new transmission route for highly pathogenic avian influenza
17 October 2024
Understanding actual “bird flu” rates in humans will help prevent further spillover and a potential new pandemic.